112 results about "Malabsorption" patented technology

A liposome-capsule dosage unit system for the delivery of a biologically active material is formed by encapsulating a biologically active materials in liposomes and then placing the liposome encapsulated material into a capsule. The capsule is typically a soft gel capsule or a two piece capsule capable of tolerating a certain amount of water. A less water tolerant capsule can be employed if the liposomes are dehydrated prior to placement within the capsule. Biologically active material include drugs, nutritional supplements, vitamins, minerals, enzymes, hormones, proteins and polypeptides. The system is especially suited for the delivery of materials with poor oral solubility, materials that are not absorbed or are poorly absorbed from the gastrointestinal tract, and materials that have conventionally been given by an invasive route. The system can be administered orally, intra-occularly, intranasally, rectally, or vaginally.

The present invention relates to methods of using GPR119 receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY, such as conditions modulated by stimulation of NPY Y2 receptor (Y2R). Agonists of GPR119 receptor are useful as therapeutic agents for treating or preventing a condition modulated by PYY, such as a condition modulated by stimulation of Y2R. Conditions modulated by PYY such as may be a condition modulated by stimulation of Y2R include bone-related conditions, metabolic disorders, angiogenesis-related conditions, ischemia-related conditions, convulsive disorders, malabsorptive disorders, cancers, and inflammatory disorders.

A composition for oral delivery of a poorly absorbed drug is disclosed. The composition includes the drug, an enhancer for increasing absorption of the drug through the intestinal mucosa, a promoter, which alone does not increase absorption of the drug through the intestinal mucosa, but which further increases the absorption of the drug in the presence of the enhancer, and optionally a protector for protecting the drug from physical or chemical decomposition or inactivation in the gastrointestinal tract. Illustrative enhancers include sucrose fatty acid esters, and illustrative promoters include aminosugars and amino acid derivatives, such as poly(amino acids). Illustrative protectors include methylcellulose, poly(vinyl alcohol), and poly(vinyl pyrrolidone).

The invention provides compositions and methods for treating pancreatic enzyme insufficiency, such as the pancreatic enzyme insufficiency associated with cystic fibrosis. The invention also provides compositions comprising lipase from Candida cylindracea, alone or in combination with amylase or amyloglucosidase, protease and / or lactase. Furthermore, the invention discloses methods for treating pancreatic enzyme insufficiency comprising administering compositions to patients in need thereof.

The invention provides a total nutrient formula food for patients with gastrointestinal malabsorption to eat, a specific total nutrient formula food or a non-total-nutrient formula food. According to the requirements of general principles of the special medical use formula food, the formula is developed by combining with the constitutive characters of the patients with gastrointestinal malabsorption and synthesizing with the research results of advanced physiology, medicine, nutriology, clinical application and the like in Harvard University at present according to the essence theories (simultaneous recuperation of the liver, the spleen and the kidneys) of supplement in digestion and balanced recuperation in the traditional Chinese medicine. According to the total nutrient formula food, essence of more than ten medicinal and edible traditional Chinese medicine extracts, a plurality of probiotics and prebiotics are taken as main raw materials, and oligopeptide, amino acid, water-soluble dietary fiber, multi-vitamin and composite minerals are taken as auxiliary materials, the total nutrient formula food not only can meet the nutritional requirements of the patients with gastrointestinal malabsorption as a single nutrient source, but also can have the efficacies of invigorating the stomach and helping digestion, warming the middle warmer and rectifying the spleen, tonifying the stomach and promoting fluid, tonifying the spleen and nourishing the stomach, helping digestion and eliminating indigestion, resolving dampness and activating the stomach, and preventing and treating gastrointestinal malabsorption.

The present invention is an improved separating device for providing the malabsorptive component of a minimally invasive weight reduction system. This device may be a sleeve, liner, or tubular sheath that alters absorption of compositions through walls of hollow organs (stomach, intestines). The improvement involves better long-term retention through the ability of the device to engage with the interserosal fibrotic tissue formed in an intussusception. The separating device may be a distal extension of a retaining member that is directly engaged with and retained by intussuscepted tissue. Intussusception shrinks a hollow organ to provide a volume reducing restrictive component of a weight reduction system. Securing the separating device to an intussusception avoids retention problems of reference art devices as interserosal fibrosis helps secure the device. Also provided are an apparatus for retaining the device, a device and method for delivering the separating device, and a method for removing it.

Disclosed is a method and composition for nutritional compositions containing glucosidase inhibitors, and more specifically Touchi Extract and its uses in the treatment of many disorders. These disorders include diabetes, hyperlipidemia, obesity, Metabolic syndrome / Syndrome X, COPD, malabsorption, Crohn's disease, diarrhea, constipation, irritable bowel syndrome, human immunodeficiency virus, cystic fibrosis, non-alcoholic steatohepatitis, polycystic ovarian syndrome including associate infertility, and erectile dysfunction. Further, glucosidase inhibitors, and more specifically Touchi Extract can be used to aid healing in critical care patients and for general wound healing. Additionally, glucosidase inhibitors, including Touchi Extract can be used to enhance athletic performance.

Disclosed are nutritional products comprising pea protein hydrolysates as a primary or sole source of protein. The nutritional products include nutritional liquids, powders, bars, and other food products, wherein the resulting nutritional products are physically stable over shelf life and provide favorable organoleptic properties. These nutritional products may be used as a nutritional source for individuals who are intolerant and / or allergic to cow milk proteins and soy proteins and / or who have malabsorption, maldigestion, or other gastroinstestinal conditions.

Disclosed herein is a pharmaceutical composition for oral absorption of polar drugs. The composition consists essentially of (a) at least one polar active substance having a bioavailability of less than 30% which is poorly absorptive through lipid membranes because of its high hydrophilicity and charged ion; (b) at least one organic alkalizing agent having an amino acid or polyol structure which shows alkalinity in aqueous solution and is ionically bonded to the polar active substance; and (c) at least one surfactant having a C6-18 fatty acid structure which has an HLB of 4 to 18. Alternatively, the composition consists essentially of (d) at least one organic alkalizing agent having the characteristics of both the organic alkalizing agent and the surfactant instead of the organic alkalizing agent and the surfactant. The composition enables polar active drugs to penetrate the gastro-intestinal membrane and oral dosage forms to be substituted for injections.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs, e.g., Factor 8) within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and / or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and / or degraded within the GI tract.